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n-Butyrate (butyrate) has been shown to amplify transgene expression in cells infected with E1-defective adenoviruses.
The present studies were undertaken in order to better define the actions of butyrate in the context of adenovirus gene
expression, and to attempt to elucidate the mechanism by which butyrate mediates the transgene amplification. It was
found that butyrate amplified viral transgene expression over a concentration range of 0.5–5 mM, and that the amplification
required an exposure of 12–24 hr for maximal effect. Western blot analysis of representative viral proteins showed that
butyrate treatment amplified DNA-binding protein, but not fiber protein. A transient adenoviral replication system suggested
that butyrate had a modest inhibitory effect on replication of the E1-defective adenovirus. Use of a specific inhibitor of
histone deacetylase, trichostatin A (TSA), reproduced the amplification of the viral transgene product achieved with the
butyrate. In contrast, adenoviral transgene expression could not be amplified by TSA treatment in a cell line known to have
a TSA-resistant histone deacetylase. Butyrate amplified steady-state gene expression of the viral transgene, but had no
detectable effects on either DNA-binding protein or fiber steady-state gene expression. Nuclear run-off experiments showed
that both butyrate and TSA caused an increase in the viral transgene transcription. It was concluded that inhibitors of
histone deacetylase amplify adenoviral transgene expression at the transcriptional level. q 1997 Academic Press
INTRODUCTION antigen (Goldberg et al., 1992), and early genes of her-
pesviridae (Anisimova et al., 1982, 1984; Ito et al., 1981;
n-Butyrate (butyrate) is a naturally occurring product
Saemundsen et al., 1980; Tanaka et al., 1991). A fourth
that has been shown to modify multiple aspects of mam-
major action is the noncompetitive inhibition of histone
malian cellular physiology. One major effect is the ability
deacetylase that leads to hyperacetylation of histones
of butyrate to produce a G1 block in multiple mammalian
(Boffa et al., 1978; Candido et al., 1978; Cousens et al.,
cell types (Charollais et al., 1990; Daniell, 1980; D’Anna
1979; Sealy and Chalkley, 1978; Vidali et al., 1978).
et al., 1980; Howard et al., 1991; Wawra et al., 1981;
Butyrate has also been shown to amplify the expres-
Wintersberger et al., 1983). A second major action con-
sion of transgene products encoded by replication-defec-
cerns the induction of differentiation, as has been dem-
tive, recombinant adenoviruses. Tang et al. reported that
onstrated in multiple neoplastic cells lines, including leu-
luciferase activity was markedly increased following bu-
kemias (Collins et al., 1978; Januszewicz et al., 1988; tyrate exposure in cells infected with an E1-defective
Leder and Leder, 1975), melanomas (Nudelman et al., adenovirus containing a cytomegalovirus (CMV)-directed
1992), and colon carcinomas (Gamet et al., 1992; Otaka luciferase-coding sequence (Tang et al., 1994). A second
et al., 1989). In this context, since butyrate is formed in group showed that butyrate increased the steady-state
the large intestine as a bacterial fermentation product of gene expression of a different recombinant adenoviral
fiber carbohydrate (Remesy and Demigne, 1976), it has transgene, the MART1 tumor antigen (Zhai et al., 1996).been speculated that increased intestinal butyrate levels Both of these groups advocated butyrate as a means for
may account for the decreased colon cancer incidence amplifying transgene expression in the context of gene
in individuals with high-fiber diets (Freeman, 1986; Ga- therapy applications.
met et al., 1992; Jass, 1985). A third class of butyrate The studies reported here were intended to better de-
actions relates to its direct modulation of transcriptional fine the effects of butyrate on transgene expression in
regulatory elements, including viral elements such as cells infected with an E1-defective adenovirus. These
those found in retroviral long terminal repeats (Bohan et experiments have defined the dose and exposure time
al., 1989; Tang and Taylor, 1990), simian virus large T requirements and assessed the effects on early and late
native adenoviral gene products. Results of experiments
performed with a specific inhibitor of histone deacetylase1 To whom reprint requests should be addressed. Fax: (205) 975-
6969. paralleled those achieved with butyrate.
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METHODS quently incubated with the membrane for 30 min, fol-
lowed by three TBST washes. The bound secondary anti-
Viruses and cell lines body was identified by incubating the membrane with
p-nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylThe E1A plasmid, pUC-E1A, contained adenovirus type
phosphate salt using the reagents and instructions of a5 nucleotides 30 to 1643. These sequences were ampli-
kit (ProtoBlot, Promega).fied by the polymerase chain reaction (PCR) from wt300
Luciferase activity was measured in cell lysates andadenoviral DNA using the primers Ad5-30F (5* ACT GAA
normalized to protein concentration as previously de-TTC TGA AGC CAA TAT GAT AAT GAG 3*) and Ad5-
scribed (Goldsmith et al., 1994).1643R (5* CTC ACT GGA GCG CCA TGC AAG TTA AAC
ATT 3*) that yielded a product of 1625 bp defined 5* by
Adenovirus replication and butyratean EcoRI site and 3* by a XhoI site. The amplified frag-
ment was subcloned into EcoRI/XhoI sites of pSL1180 The effects of butyrate on E1-defective adenovirus rep-
(Pharmacia, Piscataway, NJ), the resulting plasmid was lication were assessed by a variation of our previously
linearized with HindIII and blunted, and the adenoviral described replication-enablement system for adenovirus
sequences were excised with EcoRI followed by subclon- (Dion et al., 1996a,b; Goldsmith et al., 1994). In this sys-
ing of the blunt-ended EcoRI fragment into the EcoRI/ tem, HeLa cells are cotransduced with the AdCMV–luc
SmaI sites of pUC 13 by standard techniques. The E1B virus and plasmids encoding the E1 functions deleted
plasmid, pUC-E1B, contained adenovirus type 5 nucleo- from the virus. Two plasmids were utilized in this case,
tides 1623 to 4164 as previously described (Dion et al., pUC-E1A and pUC-E1B, which encoded the necessary
1996). The AdCMV–luc virus was provided by R. Gerard E1A and E1B proteins required for replication. The plas-
(Herz and Gerard, 1993), and the wt300 virus originally mid transduction was facilitated by complexing the DNA
described by Pilder et al. (1984) was provided by D. Curiel with a 50/50% mixture of 1,2-dioleoyl-3-trimethylam-
(University of Alabama at Birmingham, Birmingham, AL). monium-propane/L-a-dioleoyl phosphatidylethanolamine
HeLa and A549 cells were obtained directly from ATCC (Avanti Polar Lipids, Alabaster, AL) using a lipid:DNA
(Rockville, MD) and maintained in DMEM/F12 supple- ratio of 2:1 in Optimem (Life Technologies, Gaithersburg,
mented with 10% fetal calf serum (FCS). FM3A and TR303 MD). The adenovirus was added at the multiplicities of
cells (Yoshida et al., 1990) were maintained in RPMI sup- infection (m.o.i.) indicated in the text with the plasmid/
plemented with 5% FCS. lipid complexes (0.1 mg DNA/well of 24-well plate) for 4
hr, all groups performed with quadruplicate wells, after
Assessment of viral protein products which the plates were washed once with phosphate-
buffered saline (PBS) followed by the addition of normal
Adenoviral DNA-binding protein (DBP) and fiber were
growth medium (DMEM/F12, 10% fetal calf serum, 2 mM
assessed in cell lysates by Western blot analysis. Meth-
glutamine). The next day, the cells were treated with
ods used were as previously described (Goldsmith et al.,
butyrate or fresh medium as indicated in the text. One
1991) except as modified to include aprotinin (50 mg/ml)
day later, the medium was aspirated, the plates were
in the lysis buffer, and determination of protein was by
washed once with PBS, 250 ml of normal growth medium
the Bradford technique using the reagents and instruc-
was added per well, and lysates were prepared by three
tions of a kit (Bio-Rad Laboratories, Hercules, CA). The
freeze–thaw cycles. The amount of adenovirus present
proteins were size fractionated (100 mg/lane) in parallel
per milliliter of lysate was determined by 293 plaque
with protein markers (Broad-Range Markers; Bio-Rad) un-
assays as we have previously described (Dion et al.,
der denaturing conditions in a 12% sodium dodecyl sul-
1996a).
fate–polyacrylamide gel and transferred by electrical
current to nitrocellulose membranes. Following transfer, Butyrate and trichostatin treatments
membranes were briefly stained with 0.5% Ponceau S/
1% acetic acid to identify marker positions, destained Cells were infected with adenovirus at a m.o.i. of 1
except where noted in the text, for 4 hr under serum-with water, followed by incubation in TBST buffer (10
mM Tris–HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20) free conditions. Following virus exposure, the cells were
washed once with PBS and replenished with normalsupplemented with 1% bovine serum albumin at room
temperature for 1 hr. The membranes were incubated growth medium (DMEM/F12, 10% fetal calf serum, 2 mM
glutamine). The next morning, the medium was aspiratedwith either a 1:4000 dilution of the 37-3 monoclonal anti-
body directed against the DBP (Cleghon et al., 1993) or a and replaced with normal growth medium supplemented
with either butyrate or trichostatin A (TSA) as specified1:8000 dilution of the 4D2.5 monoclonal antibody directed
against adenovirus serotype 5 fiber protein (Hong and in the text. Butyrate stock was prepared as previously
described (Tang and Taylor, 1990). TSA (Wako BioPro-Engler, 1991) for 30 min, followed by three washes in
TBST buffer. A 1:20,000 dilution of alkaline phosphatase- ducts, Richmond, VA) was prepared as a 1 mg/ml stock
in dimethylsulfoxide and diluted in normal growth me-conjugated goat anti-mouse IgG (Promega) was subse-
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dium to achieve the concentrations indicated in the text.
One day later, cells were assessed for the different prod-
ucts as specified below. The butyrate or TSA concentra-
tions were varied for the dose–response curves, and the
butyrate or TSA addition times were modified for the
exposure time experiments as specified in the text.
RNA analyses
Following adenovirus and butyrate exposure, lucifer-
ase, fiber, and DBP steady-state gene expression was
analyzed in the exposed cells by Northern blot analysis
of total cellular RNA. The RNA was prepared, size frac- FIG. 2. Relationship of varying butyrate exposure time to adenoviral
transgene expression. Abscissa, 5 mM butyrate added at the time intionated on agarose, and transferred to nylon mem-
hours shown prior to harvest of cells that occurred 48 hr after virusbranes using our previously described methods (Gold-
exposure; ordinate, luciferase expression normalized to protein, withsmith et al., 1991). The luciferase probe was as pre-
cells receiving virus without butyrate serving to define 100% luciferase
viously described (Goldsmith et al., 1994), and the fiber expression. Each point is the mean of eight determinations { SEM.
gene probe was a PCR-amplified portion of the fiber gene
as previously described (Dion et al., 1996a). The DBP
RESULTSprobe was a PCR-amplified portion of the adenoviral ge-
nome (nucleotides 22458 to 22980) corresponding to the Amplification of the adenoviral transgene product was
3* end of the coding sequence as described by Kruijer butyrate-dose dependent (Fig. 1). The transgene product
et al. (1981). Probe radiolabeling, hybridization, wash, assessed in these experiments, luciferase, was quanti-
and exposure conditions were as previously described fied in lysates of cells that had been infected by AdCMV–
(Goldsmith et al., 1991). luc followed by butyrate treatment over a range of con-
Relative transcription rates of representative adenovi- centrations. No significant amplification was observed
ral genes or transgene were assessed by the nuclear over the butyrate concentration range of 0.01 to 0.1 mM.
run-off technique. HeLa cells were infected with AdCMV – As the butyrate concentration increased to 5 mM, the
luc at an m.o.i. of 1 and treated 1 day later with medium transgene amplification increased exponentially and pla-
change only, 5 mM butyrate, or 1 mM TSA for 24 hr prior teaued. As defined by these experiments, the butyrate
to harvesting of the nuclei. The methods for harvesting amplification of adenoviral transgene product required a
the nuclei, extending the transcripts, immobilizing the concentration in the 0.5 to 5 mM range.
probes, and hybridizing the probes with the transcripts Amplification of the adenoviral transgene product was
are as we have previously described (Goldsmith et al., also significantly time dependent (Fig. 2). In these experi-
1991). The probes for fiber, DBP, and luciferase were ments, butyrate was added at a fixed concentration (5
the same as those used for the Northern blot analyses. mM) for progressively longer periods prior to the cell
Counts per minute were standardized for hybridization lysate determinations that were performed 48 hr after
in all groups. The autoradiograms were exposed in a virus infection. A 1-hr butyrate exposure had no signifi-
phosphorimager for 72 hr. cant effect on the transgene content, but the transgene
content was progressively amplified as the exposure
time progressed from 4 to 24 hr before achieving a pla-
teau. These results suggest that the butyrate amplifica-
tion is both time and concentration dependent.
In order to investigate the possible effects of butyrate
treatment on native viral gene products, as opposed to
effects on the transgene expression, experiments were
performed to assess representative late and early protein
contents in the recombinant adenovirus-infected cells.
Qualitative assessment with Western blot analysis of the
cell lysates that were size fractionated under denaturing
conditions showed that fiber protein was undetectable
in the cells infected with AdCMV–luc with or without
butyrate treatment at m.o.i.’s of 1 and 10 (Fig. 3a). In
FIG. 1. Dose–response curve. Abscissa, butyrate concentration; ordi-
contrast, the monoclonal fiber antibody strongly boundnate, luciferase expression normalized to protein, with cells receiving
to a 62-kDa protein that was the expected size of the fibervirus without butyrate serving to define 100% luciferase expression.
Each point is the mean of eight determinations { SEM. monomer in cells infected with the wild-type adenovirus,
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FIG. 3. Influence of butyrate on representative late and early adenoviral protein content in adenovirus-infected cells. (a) Western blot analysis of
fiber protein. Molecular weight marker positions indicated at left, estimated size of dominant protein identified shown at right. Lane 1, sham infected;
lane 2, sham infected / butyrate; lane 3, AdCMV–luc (m.o.i.  1); lane 4, AdCMV–luc (m.o.i.  1) / butyrate; lane 5, AdCMV–luc (m.o.i.  10);
lane 6, AdCMV–luc (m.o.i.  10) / butyrate; lane 7, wt300 (m.o.i.  0.1); lane 8, wt300 (m.o.i.  0.1) / butyrate; lane 9, wt300 (m.o.i.  1.0); lane
10, wt300 (m.o.i.  1.0) / butyrate. (b) Western blot analysis of DNA-binding protein. Positions of the protein size markers shown on left, estimated
size of dominant protein identified shown at right. Lanes same as in (a).
wt300 (Chatellard and Chroboczek, 1989; Sundquist et E1A plasmid. These results strongly suggest that buty-
rate was not augmenting transgene expression as a con-al., 1973). Western blot analysis of similarly prepared
lysates showed that the early protein, DBP, was present sequence of increased viral replication.
Experiments in which adenovirus-infected cells werein the wt300-infected cells in amounts that did not appear
to vary with or without butyrate treatment (Fig. 3b). In treated with a specific histone deacetylase inhibitor
showed a viral transgene amplification that was quantita-the AdCMV–luc-infected cells, DBP was undetectable at
both m.o.i.’s without butyrate. In contrast to the results tively and qualitatively similar to that obtained with buty-
rate (Fig. 5). TSA was used to specifically inhibit histonewith fiber, butyrate treatment did result in an increase in
DBP at both m.o.i.’s of 1 and 10, although the intensity deacetylase in cells infected with the AdCMV–luc virus.
Expression of the adenoviral transgene, luciferase, wasof the band at the lower m.o.i. is not discernable on this
photograph. These results showed that, in cells infected markedly amplified in a dose-dependent fashion by TSA,
with a plateau response at 1 mM (Fig. 5a). The four-logwith the E1-defective virus, butyrate amplified the protein
content of one early viral protein and had no effect on increment in the luciferase expression obtained with TSA
was quantitatively comparable to that obtained with buty-the protein content of one late viral protein.
Viral replication assays suggested that butyrate was rate. The time dependency of the TSA exposure was
not modifying transgene expression by increasing repli-
cation of the E1-defective adenovirus (Fig. 4). It was hy-
pothesized that butyrate may act as a promiscuous viral
trans-activator, analogous to the E1A protein. In order to
test this, experiments were performed that employed a
transient viral replication assay based on our previously
described adenoviral replication-enablement system
(Goldsmith et al., 1994; Dion et al., 1996a,b), in which
the cells were simultaneously transduced with the E1-
defective virus and E1A- and/or E1B-encoding plasmids.
The combination of E1A and E1B plasmids provide the
requisite proteins for viral replication, and new virus can
be quantified in the cotransduced cell lysates at appro-
priate intervals following the cotransduction. In these ex-
FIG. 4. Effects of butyrate on E1-defective adenovirus replication.periments, a low viral m.o.i. was employed in order to
Shown is the mean adenovirus content of cell lysates as detectedmake any subtle increase in viral replication more easily
by 293 plaque assays following cotransduction with the E1-defectivedetected. The butyrate did not augment new virus pro-
adenovirus and plasmid. Abscissa, plasmid cotransduced with virus,
duction with any of the various combinations of the E1A ‘‘/B’’ indicates 5 mM butyrate treatment. Ordinate, PFU titer per ml of
and E1B plasmids, and even reduced the numbers of lysate. E1a, pUC-E1A; E1b, pUC-E1B; E1a/b, pUC-E1A/pUC-E1B; pUC,
pUC13. *No virus detected by plaque assays.progeny virus in the group receiving the virus and the
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FIG. 5. Effects of a specific histone deacetylase inhibitor on adenoviral transgene expression. (a) Dose–response curve. Abscissa, TSA concentra-
tion; ordinate, luciferase expression normalized to protein, with cells receiving virus only serving to define 100% luciferase expression. Each point
is the mean of eight determinations { SEM. (b) Relationship of varying TSA exposure time to adenoviral transgene expression. Abscissa, 1 mM
TSA added at the time in hours shown prior to harvest of cells that occurred 48 hr after virus exposure; ordinate, luciferase expression normalized
to protein, with cells receiving virus only serving to define 100% luciferase expression. Each point is the mean of eight determinations { SEM.
also similar to that observed with butyrate (Fig. 5b). The with the normally responsive histone deacetylase had
more than a four-log increment in luciferase expressionaddition of TSA at different intervals following adenovirus
infection showed that little amplification was achieved following the highest dose of TSA. In marked contrast,
the TR303 cells had a blunted response to TSA thatuntil the exposure time exceeded 4 hr. This response
was qualitatively similar to that obtained with butyrate yielded only a twofold increase at the highest dose of
TSA. These results strongly suggested that the mecha-(compare Fig. 5b to Fig. 2).
TSA treatment following adenovirus infection of a cell nism by which TSA amplified the adenoviral transgene
expression was by histone deacetylase inhibition ratherline with a histone deacetylase known to be resistant
to the effects of TSA did not result in amplification of than any other effects of TSA on the host cells.
Butyrate treatment of adenovirus-infected cellsadenoviral transgene expression (Fig. 6). The TR303 cell
line, derived from the FM3A cell line, has been shown caused an amplification of the viral transgene steady-
state RNA levels (Fig. 7). Northern blot analysis of totalto have a histone deacetylase that is resistant to the
effects of TSA (Yoshida et al., 1990). Both the parental cellular RNA obtained from HeLa cells infected with
AdCMV – luc without butyrate treatment demonstratedand the mutant cell lines were infected with AdCMV –
luc, followed by exposure to increasing doses of TSA. that the transcripts hybridizing with the luciferase
probe were undetectable under the conditions of thisThese experiments showed that the parental FM3A cells
assay. In contrast, the butyrate-treated cells had a
marked increase in a dominant 2.3-kb transcript that
specifically hybridized with the luciferase probe. The
same RNA specimens were also analyzed for fiber
and DNA-binding protein gene expression in order to
determine whether viral gene expression was also
upregulated by the butyrate treatment. These results
showed that both fiber and DBP gene expression were
undetectable in the AdCMV – luc-infected cells with or
without the butyrate. RNA from cells infected with the
wild-type, wt300 adenovirus had readily detectable
amounts of 2.2-kb transcripts in the fiber-probed blots
and 1.9-kb transcripts in the DBP-probed blots that
were similar in size to previous reports (Klessig, 1977;
Zain et al., 1979; Krujer et al., 1981). The relative
amounts of either the fiber or the DBP transcripts didFIG. 6. Adenoviral transgene expression in cell lines with varying
sensitivity to a specific histone deacetylase inhibitor. Parental FM3A not significantly vary with butyrate treatment by this
cells, or the derivative TR303 cells with a histone deacetylase that is analysis. These results suggest that butyrate treat-
not inhibited by TSA, were treated with AdCMV–luc followed by TSA ment of recombinant adenovirus-infected cells caused
treatment. Abscissa, concentration of TSA added; ordinate, luciferase
a significant increase in transgene expression, butexpression normalized to protein, with cells receiving virus only serving
had no apparent effects on the steady-state expres-to define 100% luciferase expression. Each point is the mean of eight
determinations { SEM. sion of representative late and early adenoviral genes.
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FIG. 7. Influence of butyrate on steady-state adenoviral gene expression. Shown are autoradiograms of Northern blots hybridized with the
radiolabeled probes identified above. Viruses used to infect cells prior to RNA harvest are indicated directly below probe designation. (/) Treatment
with 5 mM butyrate; (0) no treatment with butyrate. Ribosomal band intensity for actin hybridization demonstrated intact RNA of similar amounts
in all lanes (not shown). Arrows on left indicate sizes of the dominant transcripts hybridizing with the respective probes.
Nuclear run-off studies showed that butyrate or TSA DISCUSSION
increased the relative adenoviral transgene transcription
The experiments reported here have shown that buty-(Fig. 8). HeLa cells infected with AdCMV–luc were sub-
rate markedly augments adenoviral transgene expres-sequently treated with either butyrate or TSA, nuclei were
sion in a time- and dose-dependent fashion. These stud-harvested, and initiated transcripts were radiolabeled 24
ies utilized an adenovirus that contained the luciferasehr later. All groups had tubulin transcripts, and none had
coding sequence as the transgene; butyrate (5 mM) con-any hybridization to the immobilized plasmid DNA, as
sistently amplified expression of the luciferase transgeneexpected. Transcripts for fiber and DBP were not de-
by 100-fold. The magnitude of this increase is in agree-tected by this assay with or without butyrate or TSA treat-
ment with the earlier report by Tang et al., who assessedment. In marked contrast, the luciferase transcripts were
in vitro butyrate amplification in several human lung can-readily detectable in both the butyrate- and the TSA-
cer cell lines (Tang et al., 1994). These same investiga-treated groups and not in the untreated infected group.
tors found a much less consistent, and much lower, am-These results strongly suggest that both butyrate and
plification of the luciferase transgene in subcutaneouslyTSA amplified transcription of the adenoviral transgene.
engrafted tumor nodules treated by a single intratumoral
injection of butyrate. The lower amplifications observed
in vivo by these investigators are not surprising in light
of the fact that butyrate has previously been shown to
have a very brief in vivo half-life of several minutes (Miller
et al., 1987), which would significantly impact on the buty-
rate-mediated transgene amplification time and dose de-
pendency demonstrated here. Esterified butyrate deriva-
tives with longer half-lives have been developed that
might be more effective in vivo as agents for amplification
of adenoviral transgenes (Nudelman et al., 1992; Plan-
chon et al., 1991; Pouillart et al., 1992).
A specific histone deacetylase inhibitor, trichostatin
A, was helpful in delineating the probable mechanism
FIG. 8. Relative transcription of adenoviral genes or transgene. by which butyrate exerts its effects on the adenoviral
Shown are autoradiograms of radiolabeled transcripts made by the
transgene expression. TSA, originally isolated fromnuclear run-off technique hybridized to immobilized probes identified
bacteria, was shown by Yoshida et al. to function ason the right. Nuclei were harvested from cells treated as indicated
above. a specific, noncompetitive inhibitor of histone deace-
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tylase (Yoshida et al., 1990). These authors derived fied in cells infected with the E1-defective adenovirus
as determined by Western blot analysis. However, thethe TSA-resistant TR303 cell line from the parental
FM3A cell line under conditions that selected for TSA Northern blot analysis failed to detect any DBP tran-
scripts in cells infected with the E1-defective virus; inresistance, and showed by several biochemical
assays that TSA failed to modulate the activity of his- contrast, DNA-binding protein transcripts were readily
detected in cells infected with the wild-type virus in rela-tone deacetylase in the TR303 cells (Yoshida et al.,
1990). This same group subsequently demonstrated tive amounts that were not increased by butyrate. Given
the inability to detect transcripts by Northern blot analy-that the fungal metabolite, trapoxin, also inhibited his-
tone deacetylase irreversibly (Kijima et al., 1993). sis, it is not surprising that the nuclear run-off assay did
not detect any DBP transcripts in cells infected with theTaunton et al. utilized trapoxin to affinity purify a pro-
tein bound by the trapoxin that was shown to function E1-defective virus. These results suggest the possibility
that butyrate may amplify the early protein content by aas a histone deacetylase (Taunton et al., 1996). Inter-
estingly, the DNA sequence analysis of the putative posttranscriptional mechanism. The possibility that the
methods of analysis employed here were not sufficientlyhistone deacetylase isolated by this group demon-
strated a 60% homology to the yeast RPD3 gene that sensitive to detect a more subtle change in early viral
gene transcription cannot be excluded.encodes a transcriptional repressor protein (Taunton
et al., 1996). In the context of gene therapy, the possible utility of
histone deacetylase inhibitors for amplifying adenoviralThe TSA experiments reported here strongly support
the hypothesis that butyrate exerts its effects on adenovi- transgene expression is unclear. As discussed above,
the short half-life of butyrate combined with the maximalral transgene expression by inhibiting histone deacety-
lase. First, TSA produced a magnitude of transgene am- achieved levels in the low, single-digit micromolar range
limits the feasibility of systemic butyrate administrationplification similar to that achieved with butyrate, although
the concentration required was much lower. Second, the as a means of amplifying adenoviral transgene expres-
sion. A second problem is that at least one native viralkinetics of the transgene amplification in the context of
exposure time to either butyrate or TSA were very similar. protein, DBP, is amplified in concert with the adenoviral
transgene. Since multiple investigators have demon-Third, the strongest evidence was obtained by showing
that TSA amplified adenoviral transgene expression in strated that one important factor limiting the persistence
of adenoviral-infected cells is cell-mediated immunity di-FM3A cells infected with the AdCMV–luc virus, but had
a minimal effect on transgene expression in the infected rected against native viral products (Flomenberg et al.,
1996; Yang et al., 1995), manipulations that further in-TR303 cells with the histone deacetylase known to be
resistant to TSA. These experiments strongly dispute the crease native viral protein production may be disadvanta-
geous in settings where a prolonged expression of thenotion that TSA was amplifying the adenoviral transgene
via an unknown action on a pathway not requiring his- adenoviral transgene is desired.
At this point, little is known about the regulation oftone deacetylase. It seems reasonable to infer from
these experiments that all inhibitors of histone deacety- histone deacetylase in normal or diseased tissues.
Based on the findings presented here, it seems reason-lase would similarly increase adenoviral transgene ex-
pression. able to speculate that if naturally occurring differences
in histone deacetylase activity do occur, such variationsThe RNA analyses showed that both butyrate and TSA
acted to increase the relative levels of adenoviral could play a role in modulating host responses to adeno-
virus infection.transgene transcription. The Northern blots showed a
marked increase in the steady-state transgene tran-
scripts. Nuclear run-off analysis directly showed a ACKNOWLEDGMENTS
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